Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889486 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
A Phase 2 study, sponsored by Tranzyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00889486 is a Phase 2 study that has completed, run by Tranzyme. The registered enrollment target is 92 participants.
The verdict
NCT00889486, a Phase 2 study, has completed, sponsored by Tranzyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
Interventions
- DRUG Placebo
- DRUG TZP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889486
The ClinicalTrials.gov registry entry for NCT00889486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tranzyme, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00889486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00889486 about?
NCT00889486 is a clinical study titled "Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus". The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
What is the current status of trial NCT00889486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2009-04. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00889486?
The interventions under investigation include: Placebo (DRUG), TZP-102 (DRUG).
Who is sponsoring clinical trial NCT00889486?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.